TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33863661

Group type: EXPERIMENTAL
Intervention: Magmaris implantation with high endothelial shear stress (ESS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Magmaris implantation with low ESS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Magmaris implantation with intermediate ESS
Number of subjects: 22
Study: 33863713

Group type: COMPARATOR
Intervention: Synthetic data
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Real data
Number of subjects: 1543
Study: 33863774

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) parameters including time, frequency, and non-linear domains; gender and temperature.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: HRV parameters and blood biomarkers (absolute neutrophil count and C reactive protein).
Number of subjects: 203
Study: 33863803

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured by hyperinsulinemic euglycemic clamp
Number of subjects: 23

Group type: COMPARATOR
Intervention: Post-bariatric surgery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin response in women who lost weight
Number of subjects: 23
Study: 33863808

Group type: COMPARATOR
Intervention: Standard RANO
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: iRANO
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: mRANO
Number of subjects: 47
Study: 33863856

Group type: EXPERIMENTAL
Intervention: Olorinab (3 or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 1 day before colitis induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olorinab (1, 3, 10, or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 24 days after colitis induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control animals (vehicle)
Number of subjects: 0
Study: 33863913

Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant
Number of subjects: 31
Study: 33864173

Group type: EXPERIMENTAL
Intervention: Contemporary cemented rotating platform device
Number of subjects: 200
Study: 33864229

Group type: EXPERIMENTAL
Intervention: Gocovri (amantadine) 274 mg daily at bedtime
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 33864240

Group type: EXPERIMENTAL
Intervention: Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33864948

Group type: EXPERIMENTAL
Intervention: Cirrhosis (patients with cirrhosis)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No cirrhosis (patients without cirrhosis)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CLIF-C score
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: NACSELD score
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CTP score
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MELD-Na score
Number of subjects: 96
Study: 33865150

Group type: EXPERIMENTAL
Intervention: Psychoactive substances for stress management
Number of subjects: 46203

Group type: EXPERIMENTAL
Intervention: Psychoactive substances for sleep management
Number of subjects: 46203

Group type: EXPERIMENTAL
Intervention: Non-medical use (NMU) of drugs
Number of subjects: 46203

Group type: EXPERIMENTAL
Intervention: Psychostimulant medications
Number of subjects: 46203

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement (NE)
Number of subjects: 46203

Group type: EXPERIMENTAL
Intervention: Social norms and social media influence
Number of subjects: 46203
Study: 33865203

Group type: EXPERIMENTAL
Intervention: MEK inhibitor (MEKi)
Number of subjects: 62
Study: 33865400

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 32
Study: 33865434

Group type: EXPERIMENTAL
Intervention: Yimingjia adjunct therapy with desloratadine dry suspension
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo with desloratadine dry suspension
Number of subjects: 206
Study: 33865450

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) program for six months
Number of subjects: 39
Study: 33865456

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) of the dorsomedial prefrontal cortex, 20-30 sessions over 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 19
Study: 33865555

Group type: EXPERIMENTAL
Intervention: Preoperative cortical thickness
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Postoperative EEG delta power
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Interaction between mean cortical thickness and delirium status
Number of subjects: 86
Study: 33865615

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 57
Study: 33865734

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 7097
Study: 33865770

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) examination
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Higher native T1
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Higher native T2
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Higher left ventricular (LV) mass index
Number of subjects: 156
Study: 33865778

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: CMR imaging
Number of subjects: 148
Study: 33865788

Group type: EXPERIMENTAL
Intervention: LGE group (n=72)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TTE within 7 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: LGE prevalence
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Follow-up CMRI
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Myocardial fibrosis detected on CMR
Number of subjects: 104
Study: 33865810

Group type: EXPERIMENTAL
Intervention: PPG-based software algorithm for detecting AF
Number of subjects: 455699
Study: 33866464

Group type: EXPERIMENTAL
Intervention: Leptin levels in cerebrospinal fluid (CSF) before and during delayed cerebral ischemia (DCI)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Early leptin concentration in serum
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Early leptin concentration in CSF
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Clinical outcome after 12 months (extended Glasgow outcome scale)
Number of subjects: 263
Study: 33866531

Group type: EXPERIMENTAL
Intervention: Daily oral sodium selenite (dosing regimens: 33 mg daily, 11 mg BID, 5.5 mg TID)
Number of subjects: 15
Study: 33866662

Group type: EXPERIMENTAL
Intervention: Medication history interview conducted by pharmacists
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Patients taking more than 5 medications
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Adverse drug events (ADE) detected during the ED visit
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Hospitalised patients with bleeding as an ADE symptom
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Hospitalised patients with metabolic disorders as an ADE symptom
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables associated with increased hospital admission
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Medication-related variables associated with increased hospital admission
Number of subjects: 14511
Study: 33866681

Group type: EXPERIMENTAL
Intervention: JGG endoscope
Number of subjects: 21
Study: 33866818

Group type: EXPERIMENTAL
Intervention: 6- to 8-week magnetic resonance imaging (MRI)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Index multi-infarct pattern
Number of subjects: 89
Study: 33866829

Group type: EXPERIMENTAL
Intervention: HeartWare HVAD System via thoracotomy approach
Number of subjects: 144
Study: 33866938

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (single-agent paclitaxel or doxorubicin)
Number of subjects: 0
Study: 33866936

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for Rutherford 2-3
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for Rutherford 4-5
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for Rutherford 6
Number of subjects: 1189
Study: 33867192

Group type: EXPERIMENTAL
Intervention: Lenvatinib (18 mg) plus everolimus (5 mg) orally once daily
Number of subjects: 31
Study: 33867478

Group type: EXPERIMENTAL
Intervention: Atezolizumab and bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sintilimab and bevacizumab biosimilar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study: 33867481

Group type: EXPERIMENTAL
Intervention: Muscadine grape extract (MGE) capsules by mouth twice daily, 320 to 1600 mg total phenolics/d for 4 weeks
Number of subjects: 23
Study: 33868016

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 323

Group type: COMPARATOR
Intervention: Metabolically healthy obese patients
Number of subjects: 323

Group type: COMPARATOR
Intervention: Metabolically unhealthy obese patients
Number of subjects: 323
Study: 33868050

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting Only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imagery Rescripting and Schema Therapy
Number of subjects: 0
Study: 33868061

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-derived communication training for caregivers; 4 sessions of 60 minutes each
Number of subjects: 31
Study: 33868150

Group type: EXPERIMENTAL
Intervention: Early anticoagulation with Edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33868272

Group type: EXPERIMENTAL
Intervention: IP-10 expression during active TB
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: MCP-3 expression
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IL-6 expression
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IL-1RA expression
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IP-10 expression
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IL-1α expression
Number of subjects: 132
Study: 33868439

Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 33868707

Group type: EXPERIMENTAL
Intervention: Achilles tendinopathy (AT) patients
Number of subjects: 80
Study: 33869653

Group type: EXPERIMENTAL
Intervention: MND promoter-driven CAR-T cells
Number of subjects: 14

Group type: COMPARATOR
Intervention: EF1α promoter-driven CAR-T cells
Number of subjects: 14
Study: 33869765

Group type: EXPERIMENTAL
Intervention: In-office tympanostomy tube placement using a single-pass device
Number of subjects: 229
Study: 33870087

Group type: EXPERIMENTAL
Intervention: Exercise programme for deconditioned cancer survivors
Number of subjects: 0
Study: 33870149

Group type: EXPERIMENTAL
Intervention: EpAbs (INM005)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 33870151

Group type: EXPERIMENTAL
Intervention: TVB-2640 (60 mg/m) as monotherapy
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: TVB-2640 with a taxane
Number of subjects: 136
Study: 33870150

Group type: EXPERIMENTAL
Intervention: Stratified approach to care (intervention)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2300
Study: 33870413

Group type: EXPERIMENTAL
Intervention: Karius microbial cell-free DNA sequencing test (KT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Blood culture (BC) and standard microbiological testing (SMT)
Number of subjects: 55
Study: 33870484

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 1647
Study: 33870705

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion (LAAO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral Anticoagulation (OAC)
Number of subjects: 50
Study: 33871063

Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 587
Study: 33871377

Group type: EXPERIMENTAL
Intervention: Digital mental health program (Happify for Teens) for 8 weeks
Number of subjects: 800

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 800
Study: 33871700

Group type: EXPERIMENTAL
Intervention: Circulating TNFrII levels in male patients with type 2 diabetes
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Circulating TNFrII levels in female patients with type 2 diabetes
Number of subjects: 761
Study: 33871709

Group type: EXPERIMENTAL
Intervention: Chest CT scan
Number of subjects: 487

Group type: COMPARATOR
Intervention: Negative chest CT findings
Number of subjects: 487
Study: 33871807

Group type: EXPERIMENTAL
Intervention: Mongersen 160 mg/day for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mongersen (specific batch)
Number of subjects: 18
Study: 33871830

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 0
Study: 33871888

Group type: EXPERIMENTAL
Intervention: Autoantibodies to LG3 (LG3-A)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Autoantibodies to AT1R-AA
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Double-positive for LG3-A and donor-specific antibody (DSA)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Double-positive for LG3-A and AT1R-AA
Number of subjects: 93
Study: 33872131

Group type: EXPERIMENTAL
Intervention: Silver nanoparticles (exact dosage and duration not specified)
Number of subjects: 0
Study: 33872184

Group type: EXPERIMENTAL
Intervention: Internet-based onboarding procedures with human support for mHealth intervention
Number of subjects: 43
Study: 33872334

Group type: EXPERIMENTAL
Intervention: Saving Babies Lives (SBL) Care Bundle implementation
Number of subjects: 463630
Study: 33873093

Group type: EXPERIMENTAL
Intervention: Novel recombinant five-antigen Staphylococcus aureus vaccine
Number of subjects: 0
Study: 33873199

Group type: EXPERIMENTAL
Intervention: Subunit COVID-19 vaccine
Number of subjects: 0
Study: 33874911

Group type: EXPERIMENTAL
Intervention: Severe sleep disturbance
Number of subjects: 242
Study: 33874975

Group type: EXPERIMENTAL
Intervention: Oral Ty21a immunization
Number of subjects: 0
Study: 33874987

Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Vulnerable patients
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Fit patients
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Overall patients
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Frail patients across different age categories
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 1346
Study: 33875560

Group type: EXPERIMENTAL
Intervention: Direct endovascular thrombectomy (dEVT)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Bridging therapy (BT; IV tissue plasminogen activator + EVT)
Number of subjects: 226
Study: 33875611

Group type: EXPERIMENTAL
Intervention: PVSRIPO monotherapy (1, 2, or 3 injections with 21 days between injections)
Number of subjects: 12
Study: 33875845

Group type: EXPERIMENTAL
Intervention: Intravenous olipudase alfa administered every 2 weeks with intrapatient dose escalation to 3 mg/kg
Number of subjects: 20
Study: 33876222

Group type: EXPERIMENTAL
Intervention: Oral and intravenous iron tracers administered before treatment and after intensive phase (8/12 weeks) and complete treatment (24 weeks)
Number of subjects: 18
Study: 33876229

Group type: EXPERIMENTAL
Intervention: Maternal antimicrobial treatment ≥1 day before delivery
Number of subjects: 189

Group type: COMPARATOR
Intervention: No maternal antimicrobial treatment
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Overall neonatal outcomes
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Gestational age <34 weeks
Number of subjects: 189
Study: 33876337

Group type: EXPERIMENTAL
Intervention: Intra-operative monitoring of renal region tissue oxygenation (SrtO2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebral and peripheral oxygenation monitoring
Number of subjects: 0
Study: 33876469

Group type: EXPERIMENTAL
Intervention: Receiving pharmacogenomic results by mail
Number of subjects: 49
Study: 33876576

Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally twice daily
Number of subjects: 0
Study: 33877483

Group type: EXPERIMENTAL
Intervention: Asymmetrical leaflet calcification (AC)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Symmetrical leaflet calcification (SC)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Predictors for SC
Number of subjects: 567
Study: 33877496

Group type: EXPERIMENTAL
Intervention: Football training (twice weekly for six months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study: 33877661

Group type: EXPERIMENTAL
Intervention: 3D high-resolution anorectal manometry (3DHRAM)
Number of subjects: 43
Study: 33877856

Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg once daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg twice daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Belumosudil 400 mg once daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Corticosteroid (CS) treatment
Number of subjects: 54
Study: 33878018

Group type: EXPERIMENTAL
Intervention: Before the second partial lockdown
Number of subjects: 2218

Group type: COMPARATOR
Intervention: After the second partial lockdown
Number of subjects: 2218
Study: 33878020

Group type: EXPERIMENTAL
Intervention: Remote clinic visits during the COVID-19 pandemic
Number of subjects: 23

Group type: COMPARATOR
Intervention: In-person clinic visits (pre-COVID-19 cohort)
Number of subjects: 23
Study: 33878074

Group type: EXPERIMENTAL
Intervention: Hypertensive SCAD patients
Number of subjects: 318

Group type: COMPARATOR
Intervention: Normotensive SCAD patients
Number of subjects: 318
Study: 33878339

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 506

Group type: COMPARATOR
Intervention: Non-COPD control subjects
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Women with COPD
Number of subjects: 506
Study: 33878776

Group type: EXPERIMENTAL
Intervention: Uterus transplantation with immunosuppressive therapy
Number of subjects: 12
Study: 33878888

Group type: EXPERIMENTAL
Intervention: Screening for atrial fibrillation using a mobile, single-lead ECG device.
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Not undergoing screening (control group).
Number of subjects: 1019
Study: 33879078

Group type: EXPERIMENTAL
Intervention: COVID-19 as the principal cause of death
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: COVID-19 as a contributing cause of death
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Other comorbidities as the cause of death
Number of subjects: 155
Study: 33879084

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for liver fat content
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: MR elastography and vibration-controlled transient elastography for hepatic fibrosis
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Water-fat separated whole body MRI for muscle composition and body fat distribution
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI for cardiac function, structure, and tissue characteristics
Number of subjects: 400
Study: 33879090

Group type: EXPERIMENTAL
Intervention: Generative adversarial imputation nets (GAIN)
Number of subjects: 60000

Group type: COMPARATOR
Intervention: missForest
Number of subjects: 60000

Group type: COMPARATOR
Intervention: MICE
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Computation speed of GAIN
Number of subjects: 60000
Study: 33879094

Group type: COMPARATOR
Intervention: Swedish/COMPERA risk stratification method
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Novel risk stratification strategy
Number of subjects: 432
Study: 33879123

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 65
Study: 33879180

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Nodal radiotherapy
Number of subjects: 142
Study: 33879189

Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein (PSP)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) analysis for PSP
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) analysis for CRP
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) analysis for PCT
Number of subjects: 243
Study: 33879206

Group type: EXPERIMENTAL
Intervention: PARACHUTE device implantation
Number of subjects: 6
Study: 33879253

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Education/support control condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACT intervention
Number of subjects: 40
Study: 33879259

Group type: EXPERIMENTAL
Intervention: Clinic-based self-sampled HPV testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinic-based and community-based self-sampled HPV testing
Number of subjects: 0
Study: 33879263

Group type: EXPERIMENTAL
Intervention: Azithromycin (single directly observed dose)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Amoxicillin (7-day course)
Number of subjects: 300
Study: 33879458

Group type: EXPERIMENTAL
Intervention: IMU-131 (B-cell epitope vaccine)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: C3 cohort (50 μg dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: C1 and C2 cohorts (10 and 30 μg doses)
Number of subjects: 14